Alumis Presents 28-Week Data From Open Label Extension Period Of Phase 2 STRIDE Trial Of ESK-001; Says '28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75'
Portfolio Pulse from Benzinga Newsdesk
Alumis has released 28-week data from the open-label extension period of its Phase 2 STRIDE trial for ESK-001. The data indicates that ESK-001 was generally well tolerated, and most patients on the top dose achieved significant improvement in their condition.
September 27, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alumis' 28-week data from the Phase 2 STRIDE trial shows ESK-001 is well tolerated and effective, potentially boosting investor confidence.
The positive trial results for ESK-001 suggest potential for future success in further trials or market approval, which could lead to increased investor interest and a positive impact on Alumis' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90